Which funds bought or sold RVMD in Q3 2026?
Revolution Medicines Inc. 7 funds bought, 8 sold, out of 109 tracked funds that have filed for Q3 2026. Among active managers, the estimated net flow was +$807M.
Holdings as of Sep 30, 2026 (Q3 2026)13F deadline Nov 16, 2026 (45 days after quarter end)
- Fidelity+$656M
- Capital World+$298M
- Jane Street+$152M
- CPP InvestmentsNEW+$82M
- Legal & General+$48M
- CalPERS+$41M
- Duquesne+$8M
- Schwab−$189M
- UBS−$177M
- Two Sigma−$133M
- T. Rowe PriceOUT−$109M
- Adage−$107M
- General AtlanticOUT−$67M
- a16z−$28M
- Fisher Investments−$15M
Top 10 each side. NEW = opened a position, OUT = sold the whole position.
Bought (7)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| Fidelity Asset manager | Added+26.2% | +$656M | $3.2B |
| Capital World Asset manager | Added+36.2% | +$298M | $1.1B |
| Jane Street Quant & multi-strategy | Added+5411.1% | +$152M | $155M |
| CPP Investments Sovereign & pension | New | +$82M | $82M |
| Legal & General Asset manager | Added+61.3% | +$48M | $126M |
| CalPERS Sovereign & pension | Added+57.5% | +$41M | $113M |
| Duquesne Family office & foundation | Added+9.2% | +$8M | $90M |
Sold (8)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| Schwab Index giant | Trimmed-48.2% | −$189M | $204M |
| UBS Bank & broker | Trimmed-15.9% | −$177M | $941M |
| Two Sigma Quant & multi-strategy | Trimmed-87.6% | −$133M | $19M |
| T. Rowe Price Asset manager | Sold out | −$109M | — |
| Adage Hedge fund | Trimmed-87.4% | −$107M | $15M |
| General Atlantic Venture capital | Sold out | −$67M | — |
| a16z Venture capital | Trimmed-15% | −$28M | $161M |
| Fisher Investments Asset manager | Trimmed-35.2% | −$15M | $28M |
Source: SEC EDGAR Form 13F-HR for each fund, holdings as of Sep 30, 2026. Shares only (options excluded). Estimated $ = change in shares × quarter-end price. Funds may have traded since. Methodology. Not investment advice.